252 related articles for article (PubMed ID: 35247994)
21. Exercise during and after neoadjuvant rectal cancer treatment (the EXERT trial): study protocol for a randomized controlled trial.
Morielli AR; Usmani N; Boulé NG; Severin D; Tankel K; Nijjar T; Joseph K; Fairchild A; Courneya KS
Trials; 2018 Jan; 19(1):35. PubMed ID: 29329555
[TBL] [Abstract][Full Text] [Related]
22. The impact of high-intensity interval exercise training on NK-cell function and circulating myokines for breast cancer prevention among women at high risk for breast cancer.
Coletta AM; Agha NH; Baker FL; Niemiro GM; Mylabathula PL; Brewster AM; Bevers TB; Fuentes-Mattei E; Basen-Engquist K; Gilchrist SC; Simpson RJ
Breast Cancer Res Treat; 2021 Jun; 187(2):407-416. PubMed ID: 33555464
[TBL] [Abstract][Full Text] [Related]
23. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.
Shi S; Wang R; Chen Y; Song H; Chen L; Huang G
PLoS One; 2013; 8(6):e65757. PubMed ID: 23799045
[TBL] [Abstract][Full Text] [Related]
24. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
25. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
26. High-intensity interval training in patients with left ventricular assist devices: A pilot randomized controlled trial.
Moreno-Suarez I; Scheer A; Lam K; Dembo L; Spence AL; Hayward C; Kaye DM; Leet A; Fuller LM; Jacques A; Naylor LH; Green DJ; Maiorana A
J Heart Lung Transplant; 2020 Dec; 39(12):1380-1388. PubMed ID: 32958408
[TBL] [Abstract][Full Text] [Related]
27. The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy.
Thompson NA; Stewart GD; Welsh SJ; Doherty GJ; Robinson MJ; Neville BA; Vervier K; Harris SR; Adams DJ; Dalchau K; Bruce D; Demiris N; Lawley TD; Corrie PG
BMC Cancer; 2022 Jan; 22(1):99. PubMed ID: 35073853
[TBL] [Abstract][Full Text] [Related]
28. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial.
Dickhoff C; Senan S; Schneiders FL; Veltman J; Hashemi S; Daniels JMA; Fransen M; Heineman DJ; Radonic T; van de Ven PM; Bartelink IH; Meijboom LJ; Garcia-Vallejo JJ; Oprea-Lager DE; de Gruijl TD; Bahce I
BMC Cancer; 2020 Aug; 20(1):764. PubMed ID: 32795284
[TBL] [Abstract][Full Text] [Related]
29. Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design.
Garrido P; Pujol JL; Kim ES; Lee JM; Tsuboi M; Gómez-Rueda A; Benito A; Moreno N; Gorospe L; Dong T; Blin C; Rodrik-Outmezguine V; Passos VQ; Mok TS
Future Oncol; 2021 Apr; 17(12):1459-1472. PubMed ID: 33648347
[TBL] [Abstract][Full Text] [Related]
30. Thioredoxin activity confers resistance against oxidative stress in tumor-infiltrating NK cells.
Yang Y; Neo SY; Chen Z; Cui W; Chen Y; Guo M; Wang Y; Xu H; Kurzay A; Alici E; Holmgren L; Haglund F; Wang K; Lundqvist A
J Clin Invest; 2020 Oct; 130(10):5508-5522. PubMed ID: 32673292
[TBL] [Abstract][Full Text] [Related]
31. A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II-IIIA non-small cell lung cancer: study protocol for a randomized controlled trial.
Saka H; Kitagawa C; Ichinose Y; Takenoyama M; Ibata H; Kato T; Takami K; Yamashita M; Maeda T; Takeo S; Ueda H; Okabayashi K; Nagashima S; Oka T; Kouso H; Fukuyama S; Yoshimoto K; Shimokawa M; Saito AM; Ito S
Trials; 2017 Sep; 18(1):429. PubMed ID: 28915900
[TBL] [Abstract][Full Text] [Related]
32. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.
Moon EK; Langer CJ; Albelda SM
Ann Am Thorac Soc; 2017 Aug; 14(8):1248-1260. PubMed ID: 28613923
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy for non-small-cell lung cancer.
Thomas A; Jakopovic M
Expert Opin Biol Ther; 2014 Aug; 14(8):1061-4. PubMed ID: 24878420
[TBL] [Abstract][Full Text] [Related]
34. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
35. Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients.
Lin M; Luo H; Liang S; Chen J; Liu A; Niu L; Jiang Y
J Clin Invest; 2020 May; 130(5):2560-2569. PubMed ID: 32027620
[TBL] [Abstract][Full Text] [Related]
36. The Impact of a Multidimensional Exercise Intervention on Physical and Functional Capacity, Anxiety, and Depression in Patients With Advanced-Stage Lung Cancer Undergoing Chemotherapy.
Quist M; Adamsen L; Rørth M; Laursen JH; Christensen KB; Langer SW
Integr Cancer Ther; 2015 Jul; 14(4):341-9. PubMed ID: 25800229
[TBL] [Abstract][Full Text] [Related]
37. A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol.
Miura S; Naito T; Mitsunaga S; Omae K; Mori K; Inano T; Yamaguchi T; Tatematsu N; Okayama T; Morikawa A; Mouri T; Tanaka H; Kimura M; Imai H; Mizukami T; Imoto A; Kondoh C; Shiotsu S; Okuyama H; Ueno M; Takahashi T; Tsuji T; Aragane H; Inui A; Higashiguchi T; Takayama K
BMC Cancer; 2019 May; 19(1):528. PubMed ID: 31151425
[TBL] [Abstract][Full Text] [Related]
38. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
[TBL] [Abstract][Full Text] [Related]
39. Immunological markers of anti-tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancer.
Skachkova OV; Khranovska NM; Gorbach OI; Svergun NM; Sydor RI; Nikulina VV
Exp Oncol; 2013 Jun; 35(2):109-13. PubMed ID: 23828386
[TBL] [Abstract][Full Text] [Related]
40. The influence of a supervised group exercise intervention combined with active lifestyle recommendations on breast cancer survivors' health, physical functioning, and quality of life indices: study protocol for a randomized and controlled trial.
Riani Costa LA; F Barreto R; de Leandrini SMM; Gurgel ARB; de Sales GT; Voltarelli VA; de Castro G; Fenton SAM; Turner JE; Klausener C; Neves LM; Ugrinowitsch C; Farah JC; Forjaz CLM; Brito CMM; Brum PC
Trials; 2021 Dec; 22(1):934. PubMed ID: 34922621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
